In the BioHarmony Drug Report Database

"Preview" Icon

Tenofovir alafenamide

Vemlidy (tenofovir alafenamide) is a small molecule pharmaceutical. Tenofovir alafenamide was first approved as Vemlidy on 2016-11-10. It is used to treat chronic hepatitis b in the USA. It has been approved in Europe to treat hepatitis b. Genvoya’s patents are valid until 2032-08-15 (FDA).

 

Trade Name

 

Vemlidy
 

Common Name

 

tenofovir alafenamide
 

ChEMBL ID

 

CHEMBL2107825
 

Indication

 

chronic hepatitis b, hepatitis b
 

Drug Class

 

Antivirals

Image (chem structure or protein)

Tenofovir alafenamide structure rendering